Azienda Ospedaliera CittÃ della Salute e della Scienza di Torino Trials

Azienda Ospedaliera CittÃ della Salute e della Scienza di Torino	Welcome, Profile Billing Logout

35 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Zola, Paolo

PAPAudit, NCT04812938: Exploiting Pathogenic Tp53 Mutation for Early Diagnosis of Ovarian Cancer by Mean of Papanicolau Test

Not yet recruiting

N/A

190

Europe

Patients with Ovarian cancer and pap test available

Azienda Ospedaliera San Giovanni Battista, Humanitas Hospital, Italy

Ovarian Cancer

04/22

10/22

Fanelli, Vito

NCT06224010: Respiratory Drive and Inspiratory Effort in COVID-19 Associated ARDS

Completed

N/A

Europe

Respiratory drive and effort assessment

University of Turin, Italy

ARDS, Human, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome, Respiratory Effort-Related Arousal, Weaning Failure, Mechanical Ventilation Complication, Acute Hypoxic Respiratory Failure

06/23

EuroECMO-COVID, NCT04366921: European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO

Recruiting

N/A

150

Europe, RoW

Maastricht University Medical Center, European chapter of the Extracorporeal Life Support Organization, Erasmus Medical Center, Leiden University Medical Center, UMC Utrecht, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Papa Giovanni XXIII Hospital, Niguarda Hospital, Ospedale San Donato, Ospedale S. Giovanni Bosco, IRCCS Policlinico S. Matteo, The Mediterranean Institute for Transplantation and Advanced Specialized Therapies, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Ospedale dell'Angelo, Venezia-Mestre, University Hospital, Udine, Italy, San Gerardo Hospital, Ospedali Riuniti Ancona, San Camillo Hospital, Rome, San Giorgio Clinic, GVM Care & Research, San Raffaele University Hospital, Italy, Ospedale San Bortolo di Vicenza, Klinik Hirslanden, Zurich, University of Zurich, Cardiocentro Ticino, Vilnius University Hospital Santaros Klinikos, Universitätsklinikum Düsseldorf, Klinikum Nürnberg, Hannover Medical School, Heart Center Leipzig - University Hospital, University Hospital Regensburg, University Hospital, Essen, German Heart Center, University Hospital, Aachen, University Heart Center Freiburg - Bad Krozingen, Klinikum Kassel, General University Hospital, Prague, Universitaire Ziekenhuizen Leuven, Onze Lieve Vrouwziekenhuis Aalst, Erasme University Hospital, University Hospital, Antwerp, Hôpital Civil Marie Curie de Charleroi, University Hospital, Ghent, Centre Hospitalier Universitaire Saint Pierre, Hospital Vall d'Hebron, Hospital Universitario Ramon y Cajal, Hospital Miguel Servet, Henri Mondor University Hospital, Hospices Civils de Lyon, Pitié-Salpêtrière Hospital, Rennes University Hospital, Guy's and St Thomas' NHS Foundation Trust, Karolinska University Hospital, Hospital Sao Joao, Medical University of Warsaw, Universitätskliniken Innsbruck, Medical University of Vienna, University Hospital, Alexandroupolis, Novosibirsk City Hospital #2, City Clinical Hospital No. 67, Moscow, Russia, City Hospital No 40, Saint Petersburg, Russia, Krasnodar Regional Hospital no 1, Kemerovo Regional Clinical Cardiological Center named after academician L.S. Barbarash, City Hospital No 41, Ekaterinburg, Russia, G. Pasquinucci Heart Hospital, Massa, Charles University, Czech Republic, University Hospital, Bordeaux, Bambino Gesù Hospital and Research Institute, Policlinico Hospital Milan, Gaslini Children's Hospital, Children's Medical Hospital, University of Essen, Essen, Germany, University Hospital, Geneva, Newcastle-upon-Tyne Hospitals NHS Trust, Paediatric Intensive Care Glasgow, Paris South University Hospitals, University of Groningen, Great Ormond Street Hospital for Children NHS Foundation Trust, Hospital Sant Joan de Deu, Heim Pal Children's Hospital, University Hospital, Montpellier, Royal Brompton & Harefield NHS Foundation Trust, Lund University Hospital, Landesklinikum Sankt Polten, Chelyabinsk Regional Clinical Hospital, ECMO Centers Israel, Copenhagen University Hospital at Herlev, Ospedale M. Bufalini Cesena, A.O.U. Città della Salute e della Scienza - Molinette Hospital, Mauriziano Umberto I Hospital, University of Bern, University Hospital, Basel, Switzerland, University of Lausanne Hospitals, University Hospital Tuebingen, Universitätsklinikum Köln, Chirec, Universitair Ziekenhuis Brussel, Centre Hospitalier Universitaire de Liège, La Louvière Hopital, Leicester Royal Infirmary NHS Trust

COVID, SARS-CoV-2, ARDS, Human, Refractory Hypoxemia, Cardiogenic Shock, Septic Shock, Extracorporeal Membrane Oxygenation

04/22

PROMIZING, NCT02447692: Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The Study

Completed

N/A

575

Europe, Canada, RoW

PSV ventilation strategy, PAV+ ventilation strategy

Lawson Health Research Institute, Canadian Institutes of Health Research (CIHR), Medtronic, Canadian Critical Care Trials Group

Critically Ill, Acute Respiratory Failure

07/24

Fabi, Alessandra

YAPPETIZER, NCT03358017: Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer

Completed

Europe

Zoledronate, zoledronic acid, Atorvastatin 80mg, Standard neoadjuvant cht

Mario Negri Institute for Pharmacological Research, Associazione Italiana per la Ricerca sul Cancro

Triple Negative Breast Cancer

06/21

07/23

GIM24-PALBO-BP, NCT04318223 / 2019-000221-45: Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

Recruiting

168

Europe

Palbociclib

Consorzio Oncotech

Metastatic Breast Cancer, Locally Advanced Breast Cancer

07/23

HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients

Active, not recruiting

Europe

Abemaciclib, Aromatase Inhibitors

University of Milano Bicocca

Advanced Breast Cancer

12/23

NCT05266937: Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Active, not recruiting

Europe

Atezolizumab,Paclitaxel, Carboplatin

Consorzio Oncotech

Metastatic Breast Cancer, Triple Negative Breast Cancer, PD-L1 Gene Mutation

07/24

AZALEA, NCT06690840: Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients

Not yet recruiting

Europe

Atezolizumab in combination with Cyclophosphamide and Vinorelbine

European Institute of Oncology

Triple Negative Breast Cancer

12/26

02/27

Neo-AGILE, NCT06259929: NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer

Recruiting

Europe

Abemaciclib 150 MG + Giredestrant 30 MG

Fondazione Oncotech

Breast Cancer

04/26

04/27

PHERGAIN-2, NCT04733118 / 2020-003205-66: Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

Active, not recruiting

393

Europe

Trastuzumab and Pertuzumab (FDC SC) and T-DM1, Trastuzumab emtansine, Phesgo, Kadcyla

MedSIR, Hoffmann-La Roche

Early Breast Cancer

09/25

03/28

PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Recruiting

220

Europe

Giredestrant, Triptorelin, Anastrozole

ETOP IBCSG Partners Foundation, Hoffmann-La Roche

Breast Cancer

06/26

ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting

1/2

Europe, US, RoW

Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio

Stemline Therapeutics, Inc., Stemline Therapeutics, Inc

Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases

12/25

BDMO, NCT06367491: National Database of Bone Metastases

Recruiting

N/A

800

Europe

Registration in a database

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Bone Metastases

01/30

BIO-META, NCT02284581: Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments

Recruiting

N/A

10000

Europe

Consorzio Oncotech

Metastatic Breast Cancer

06/23

12/25

GIM21, NCT05735392: Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer ( Trial)

Completed

N/A

Europe

Both blood and tissues collection for patients with metastatic breast cancer HER2+ pretreated with no more than one line of anti-HER2 therapy for advanced breast cancer.

Consorzio Oncotech

Metastatic Breast Cancer

01/22

GIM28-ELMER, NCT06894173: EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase

Recruiting

N/A

1000

Europe

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Breast Cancer

12/25

12/26

CYCLHER, NCT06243432: Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer

Recruiting

N/A

600

Europe

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Advanced Breast Carcinoma

12/24

03/25

STILVARCA, NCT05748353: Endocrine Disruptors and Life STILe in Breast Cancer Development

Active, not recruiting

N/A

275

Europe

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Breast Cancer, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer, Life Style, Cadmium Exposure

06/24

07/24

PALMARES-2, NCT06805812: Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian Study

Recruiting

N/A

3500

Europe

Palbociclib, Ribociclib, Abemaciclib

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, European Institute of Oncology, Italy, Humanitas Research Hospital IRCCS, Rozzano-Milan, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, OSPEDALE ASST CREMONA, IOV Oncologico Veneto Padova, ASST Fatebenefratelli Sacco, IRCCS Fondazione Salvatore Maugeri, Pavia, Italy, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori Meldola, Azienda Ospedaliero-Universitaria di Modena, Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, A.O.U. Federico II, Napoli, San Raffaele University Hospital, Italy, Centro di Riferimento Oncologico - Aviano, Azienda Socio-Sanitaria Territoriale Lariana, Azienda ULSS 3 Serenissima, Ospedale di Mirano, Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma, Fondazione IRCCS Policlinico San Matteo di Pavia, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Ospedaliero-Universitaria Careggi, Humanitas, Istituto Clinico Catanese, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Fondazione Policlinico Universitario Campus Bio-Medico, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer, Metastatic, Breast Carcinoma, Breast Diseases, Breast Neoplasms, Breast Neoplasms, Male, Breast Cancer, Breast Cancer With Metastatic Bone Disease, Breast Cancers, Breast Neoplasm, Breast Tumors, HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer, HR+ Advanced or Metastatic Breast Cancer, HR+/HER2- Breast Cancer, HRpos Breast Neoplasms, HR-positive, HER2-negative Advanced Breast Cancer, HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer, HR-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Breast Neoplasms, Hormone Receptor Positive HER-2 Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Hormone Receptor Positive Metastatic Breast Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer, Hormone Receptor Negative Breast Cancer, Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer, Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Hormone Receptor (HR)-Positive Breast Cancer, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Palbociclib, Ribociclib, Abemaciclib, CDK4/6 Inhibitor, CDK4/6 Inhibitors

12/30

12/40

NEORISK, NCT06441240: Evaluation of Recurrence Risk Factors in Locally Advanced Breast Cancer Patients Underwent Neoadjuvant Chemotherapy.

Recruiting

N/A

933

Europe

MRI

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Breast Cancer, Chemotherapy Effect, Triple Negative Breast Cancer, Recurrence, Local Neoplasm, Risk Factors

12/25

03/26

NCT06137833: Wide Spectrum Micronutrients Supplementation in Patients with Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy

Recruiting

N/A

Europe

APPOPRTAL®, Placebo

Pharmanutra S.p.a., Latis S.r.l.

Fatigue, Breast Cancer

06/25

PERGIQUAL, NCT05893368: New Model for Integrating Person-based Care (PbC) in the Treatment of Advanced HER2-negative Breast Cancer

Recruiting

N/A

Europe

Sharing all key aspects associated with the quality of life in a single digital environment

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Advanced Breast Cancer

01/25

02/25

PROMETA, NCT06261918: Transcriptional and Epimetabolic Profile of Breast Carcinoma With Luminal or HER2+ or Locally Advanced Triple-negative Histotype in Patients With/Without Previous Clinical History of Metabolic Syndrome

Recruiting

N/A

120

Europe

Influence of metabolic syndrome on the achievement of pathological complete response

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Breast Cancer, Metabolic Syndrome

02/25

07/26

DIAMOND, NCT05919212: Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy

Recruiting

N/A

Europe

HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Metastatic Breast Cancer

06/24

02/26

SILMET, NCT05689619: SILibinin in NSCLC and BC Patients With Single Brain METastasis

Recruiting

N/A

Europe

Silibinin, Sillbrain, Placebo

Azienda Ospedaliera Città della Salute e della Scienza di Torino

Brain Metastases, Adult, Non Small Cell Lung Cancer, Breast Cancer

09/25

09/27

PERSEVEREX, NCT06807749: Adjuvant Treatment in Premenopausal Breast Cancer

Not yet recruiting

N/A

800

Europe

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Clinical Research Technology S.r.l.

Breast Cancer Early Stage Breast Cancer (Stage 1-3)

09/26

09/27

IDENTITY, NCT05835739: InheriteD brEast caNcer iTalian regIsTrY A Retrospective-prospective Observational Cohort Study to Evaluate Cancer Prevention Strategies in Women With a Deleterious Mutation in BRCA1-2

Recruiting

N/A

Europe

Centro di Riferimento Oncologico - Aviano

Breast Cancer

09/25

09/35

Ciccone, Giovannino

ERAS-Colon, NCT04037787: ERAS (Enhanced Recovery After Surgery) Protocol Implementation in Piedmont Region for Colorectal Cancer Surgery

Completed

N/A

2397

Europe

ERAS protocol, ERAS (Enhanced Recovery After Surgery) protocol

Ospedale Santa Croce-Carle Cuneo, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Ministry of Health, Italy, Regione Piemonte

Colorectal Cancer, Quality Improvement, Perioperative Care, Recovery of Function

05/21

11/21

ERAS-Gyneco, NCT04063072: ERAS (Enhanced Recovery After Surgery) Protocol Implementation in Piedmont Region for Hysterectomy.

Recruiting

N/A

1800

Europe

ERAS protocol, ERAS (Enhanced Recovery After Surgery) protocol

Ospedale Regina Montis Regalis, Martini Hospital, Turin, Italy, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Ministry of Health, Italy, Regione Piemonte

Uterine Neoplasms

07/21

10/21

PAPAudit, NCT04812938: Exploiting Pathogenic Tp53 Mutation for Early Diagnosis of Ovarian Cancer by Mean of Papanicolau Test

Not yet recruiting

N/A

190

Europe

Patients with Ovarian cancer and pap test available

Azienda Ospedaliera San Giovanni Battista, Humanitas Hospital, Italy

Ovarian Cancer

04/22

10/22

Pellerino, Alessia

ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

	Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
	Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma

Recruiting

450

Europe, Canada, Japan, US, RoW

Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo

Chimerix

H3 K27M, Glioma

08/26

NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

	Jan 2023 - Jun 2023 : Data from trial for glioblastoma
	Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults

Active, not recruiting

210

Europe, US

Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine

CNS Pharmaceuticals, Inc., Worldwide Clinical Trials

Glioblastoma Multiforme, Adult

12/24

03/25

GLIOSTAR, NCT04573192: A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression

Recruiting

1/2

142

Europe

L19TNF, onfekafusp alfa, Lomustine

Philogen S.p.A.

Glioblastoma

03/25

12/25

SILMET, NCT05689619: SILibinin in NSCLC and BC Patients With Single Brain METastasis

Recruiting

N/A

Europe

Silibinin, Sillbrain, Placebo

Azienda Ospedaliera Città della Salute e della Scienza di Torino

Brain Metastases, Adult, Non Small Cell Lung Cancer, Breast Cancer

09/25

09/27

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Zola, Paolo

PAPAudit, NCT04812938: Exploiting Pathogenic Tp53 Mutation for Early Diagnosis of Ovarian Cancer by Mean of Papanicolau Test

Not yet recruiting

N/A

190

Europe

Patients with Ovarian cancer and pap test available

Azienda Ospedaliera San Giovanni Battista, Humanitas Hospital, Italy

Ovarian Cancer

04/22

10/22

Fanelli, Vito

NCT06224010: Respiratory Drive and Inspiratory Effort in COVID-19 Associated ARDS

Completed

N/A

Europe

Respiratory drive and effort assessment

University of Turin, Italy

06/23

EuroECMO-COVID, NCT04366921: European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO

Recruiting

N/A

150

Europe, RoW

COVID, SARS-CoV-2, ARDS, Human, Refractory Hypoxemia, Cardiogenic Shock, Septic Shock, Extracorporeal Membrane Oxygenation

04/22

PROMIZING, NCT02447692: Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The Study

Completed

N/A

575

Europe, Canada, RoW

PSV ventilation strategy, PAV+ ventilation strategy

Lawson Health Research Institute, Canadian Institutes of Health Research (CIHR), Medtronic, Canadian Critical Care Trials Group

Critically Ill, Acute Respiratory Failure

07/24

Fabi, Alessandra

YAPPETIZER, NCT03358017: Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer

Completed

Europe

Zoledronate, zoledronic acid, Atorvastatin 80mg, Standard neoadjuvant cht

Mario Negri Institute for Pharmacological Research, Associazione Italiana per la Ricerca sul Cancro

Triple Negative Breast Cancer

06/21

07/23

Recruiting

168

Europe

Palbociclib

Consorzio Oncotech

Metastatic Breast Cancer, Locally Advanced Breast Cancer

07/23

HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients

Active, not recruiting

Europe

Abemaciclib, Aromatase Inhibitors

University of Milano Bicocca

Advanced Breast Cancer

12/23

NCT05266937: Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Active, not recruiting

Europe

Atezolizumab,Paclitaxel, Carboplatin

Consorzio Oncotech

Metastatic Breast Cancer, Triple Negative Breast Cancer, PD-L1 Gene Mutation

07/24

AZALEA, NCT06690840: Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients

Not yet recruiting

Europe

Atezolizumab in combination with Cyclophosphamide and Vinorelbine

European Institute of Oncology

Triple Negative Breast Cancer

12/26

02/27

Neo-AGILE, NCT06259929: NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer

Recruiting

Europe

Abemaciclib 150 MG + Giredestrant 30 MG

Fondazione Oncotech

Breast Cancer

04/26

04/27

PHERGAIN-2, NCT04733118 / 2020-003205-66: Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

Active, not recruiting

393

Europe

Trastuzumab and Pertuzumab (FDC SC) and T-DM1, Trastuzumab emtansine, Phesgo, Kadcyla

MedSIR, Hoffmann-La Roche

Early Breast Cancer

09/25

03/28

PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Recruiting

220

Europe

Giredestrant, Triptorelin, Anastrozole

ETOP IBCSG Partners Foundation, Hoffmann-La Roche

Breast Cancer

06/26

ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting

1/2

Europe, US, RoW

Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio

Stemline Therapeutics, Inc., Stemline Therapeutics, Inc

Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases

12/25

BDMO, NCT06367491: National Database of Bone Metastases

Recruiting

N/A

800

Europe

Registration in a database

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Bone Metastases

01/30

BIO-META, NCT02284581: Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments

Recruiting

N/A

10000

Europe

Consorzio Oncotech

Metastatic Breast Cancer

06/23

12/25

GIM21, NCT05735392: Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer ( Trial)

Completed

N/A

Europe

Both blood and tissues collection for patients with metastatic breast cancer HER2+ pretreated with no more than one line of anti-HER2 therapy for advanced breast cancer.

Consorzio Oncotech

Metastatic Breast Cancer

01/22

GIM28-ELMER, NCT06894173: EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase

Recruiting

N/A

1000

Europe

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Breast Cancer

12/25

12/26

CYCLHER, NCT06243432: Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer

Recruiting

N/A

600

Europe

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Advanced Breast Carcinoma

12/24

03/25

STILVARCA, NCT05748353: Endocrine Disruptors and Life STILe in Breast Cancer Development

Active, not recruiting

N/A

275

Europe

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Breast Cancer, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer, Life Style, Cadmium Exposure

06/24

07/24

Recruiting

N/A

3500

Europe

Palbociclib, Ribociclib, Abemaciclib

12/30

12/40

NEORISK, NCT06441240: Evaluation of Recurrence Risk Factors in Locally Advanced Breast Cancer Patients Underwent Neoadjuvant Chemotherapy.

Recruiting

N/A

933

Europe

MRI

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Breast Cancer, Chemotherapy Effect, Triple Negative Breast Cancer, Recurrence, Local Neoplasm, Risk Factors

12/25

03/26

NCT06137833: Wide Spectrum Micronutrients Supplementation in Patients with Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy

Recruiting

N/A

Europe

APPOPRTAL®, Placebo

Pharmanutra S.p.a., Latis S.r.l.

Fatigue, Breast Cancer

06/25

PERGIQUAL, NCT05893368: New Model for Integrating Person-based Care (PbC) in the Treatment of Advanced HER2-negative Breast Cancer

Recruiting

N/A

Europe

Sharing all key aspects associated with the quality of life in a single digital environment

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Advanced Breast Cancer

01/25

02/25

Recruiting

N/A

120

Europe

Influence of metabolic syndrome on the achievement of pathological complete response

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Breast Cancer, Metabolic Syndrome

02/25

07/26

DIAMOND, NCT05919212: Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy

Recruiting

N/A

Europe

HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Metastatic Breast Cancer

06/24

02/26

SILMET, NCT05689619: SILibinin in NSCLC and BC Patients With Single Brain METastasis

Recruiting

N/A

Europe

Silibinin, Sillbrain, Placebo

Azienda Ospedaliera Città della Salute e della Scienza di Torino

Brain Metastases, Adult, Non Small Cell Lung Cancer, Breast Cancer

09/25

09/27

PERSEVEREX, NCT06807749: Adjuvant Treatment in Premenopausal Breast Cancer

Not yet recruiting

N/A

800

Europe

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Clinical Research Technology S.r.l.

Breast Cancer Early Stage Breast Cancer (Stage 1-3)

09/26

09/27

Recruiting

N/A

Europe

Centro di Riferimento Oncologico - Aviano

Breast Cancer

09/25

09/35

Ciccone, Giovannino

ERAS-Colon, NCT04037787: ERAS (Enhanced Recovery After Surgery) Protocol Implementation in Piedmont Region for Colorectal Cancer Surgery

Completed

N/A

2397

Europe

ERAS protocol, ERAS (Enhanced Recovery After Surgery) protocol

Ospedale Santa Croce-Carle Cuneo, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Ministry of Health, Italy, Regione Piemonte

Colorectal Cancer, Quality Improvement, Perioperative Care, Recovery of Function

05/21

11/21

ERAS-Gyneco, NCT04063072: ERAS (Enhanced Recovery After Surgery) Protocol Implementation in Piedmont Region for Hysterectomy.

Recruiting

N/A

1800

Europe

ERAS protocol, ERAS (Enhanced Recovery After Surgery) protocol

Ospedale Regina Montis Regalis, Martini Hospital, Turin, Italy, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Ministry of Health, Italy, Regione Piemonte

Uterine Neoplasms

07/21

10/21

PAPAudit, NCT04812938: Exploiting Pathogenic Tp53 Mutation for Early Diagnosis of Ovarian Cancer by Mean of Papanicolau Test

Not yet recruiting

N/A

190

Europe

Patients with Ovarian cancer and pap test available

Azienda Ospedaliera San Giovanni Battista, Humanitas Hospital, Italy

Ovarian Cancer

04/22

10/22

Pellerino, Alessia

ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

	Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
	Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma

Recruiting

450

Europe, Canada, Japan, US, RoW

Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo

Chimerix

H3 K27M, Glioma

08/26

NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

	Jan 2023 - Jun 2023 : Data from trial for glioblastoma
	Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults

Active, not recruiting

210

Europe, US

Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine

CNS Pharmaceuticals, Inc., Worldwide Clinical Trials

Glioblastoma Multiforme, Adult

12/24

03/25

GLIOSTAR, NCT04573192: A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression

Recruiting

1/2

142

Europe

L19TNF, onfekafusp alfa, Lomustine

Philogen S.p.A.

Glioblastoma

03/25

12/25

SILMET, NCT05689619: SILibinin in NSCLC and BC Patients With Single Brain METastasis

Recruiting

N/A

Europe

Silibinin, Sillbrain, Placebo

Azienda Ospedaliera Città della Salute e della Scienza di Torino

Brain Metastases, Adult, Non Small Cell Lung Cancer, Breast Cancer

09/25

09/27

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites